

Danielle M Brander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6979861/publications.pdf>

Version: 2024-02-01

69
papers

2,421
citations

430874

18
h-index

206112

48
g-index

69
all docs

69
docs citations

69
times ranked

2232
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	27.0	706
2	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	3.5	329
3	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 230-240.	10.7	287
4	Umbralisib, a novel PI3K γ and casein kinase-1 μ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>Lancet Oncology</i> , The, 2018, 19, 486-496.	10.7	178
5	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , 2018, 103, 1511-1517.	3.5	135
6	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
7	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
8	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , the, 2019, 6, e419-e428.	4.6	60
9	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55
10	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K γ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	1.4	38
11	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. <i>Blood</i> , 2015, 126, 830-830.	1.4	38
12	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	1.4	32
13	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , 2021, 138, 836-846.	1.4	27
14	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27
15	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
16	<scp>SET</scp> alpha and <scp>SET</scp> beta <scp>mRNA</scp> isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 605-615.	2.5	24
17	TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 4154-4154.	1.4	20
18	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018, 132, 6-6.	1.4	18
20	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
21	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e407-e414.	4.6	16
22	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	1.4	16
23	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	1.4	16
24	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	1.4	15
25	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , 2021, 138, 392-392.	1.4	15
26	Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation. <i>Blood</i> , 2018, 132, 297-297.	1.4	14
27	TGR-1202, a Novel Once Daily PI3K $\hat{\imath}$ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1984-1984.	1.4	14
28	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
29	A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy. <i>Medical Mycology Case Reports</i> , 2020, 27, 17-21.	1.3	10
30	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	7.2	10
31	Activity of TGR-1202, a novel once-daily PI3K $\hat{\imath}$ inhibitor, in patients with relapsed or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2513-2513.	1.6	10
32	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. <i>Blood</i> , 2021, 138, 2628-2628.	1.4	10
33	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
34	Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL. <i>Blood</i> , 2019, 134, 3036-3036.	1.4	9
35	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
36	A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 21-22.	1.4	8

#	ARTICLE	IF	CITATIONS
37	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 2033-2033.	1.4	6
38	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2627-2630.	1.3	5
39	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. <i>Blood</i> , 2018, 132, 183-183.	1.4	5
40	Comparison of the PI3K- γ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro. <i>Blood</i> , 2012, 120, 3914-3914.	1.4	5
41	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	1.4	4
42	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	1.4	4
43	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3
44	Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib. Patient Preference and Adherence, 2012, 6, 239.	1.8	2
45	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , 2018, 132, 3142-3142.	1.4	2
46	Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 5658-5658.	1.4	2
47	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016, 128, 4400-4400.	1.4	2
48	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 3321-3321.	1.4	2
49	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
50	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	1.4	1
51	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	1.4	1
52	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	1.4	1
53	Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients. <i>Blood</i> , 2018, 132, 5540-5540.	1.4	1
54	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , 2018, 132, 4759-4759.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1
56	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq0 00rgBT /Overlock 10	1.4	0
57	Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the Bâ€cell receptor pathway and antiâ€apoptotic inhibitors: how do we mix, match, and move forward?. <i>British Journal of Haematology</i> , 2017, 176, 337-340.	2.5	0
58	Postâ€translational regulation could be determine functional differences between <sc>SET</sc> alpha and beta isoform â€ Response to CristÃ³bal <i>etÂal</i>. <i>British Journal of Haematology</i> , 2019, 186, 637-637.	2.5	0
59	The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome. <i>Blood</i> , 2011, 118, 2850-2850.	1.4	0
60	Circulating B Cell Clones in Familial Waldenströ̀m Macroglobulinemia.. <i>Blood</i> , 2012, 120, 2703-2703.	1.4	0
61	Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1626-1626.	1.4	0
62	Laboratory Correlates and a Phase I Clinical Trial Of Lenalidomide In Combination With Plerixafor In Patients With Previously Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 5301-5301.	1.4	0
63	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , 2018, 132, 4410-4410.	1.4	0
64	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
65	Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team. <i>Blood</i> , 2019, 134, 5878-5878.	1.4	0
66	Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis. <i>Blood</i> , 2019, 134, 4004-4004.	1.4	0
67	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019, 134, 3048-3048.	1.4	0
68	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
69	Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. <i>European Journal of Haematology</i> , 2022, , .	2.2	0